retatrutide phase 3 trial results What caught my attention wasn't just the number. It was what the number represents. New data for showed an average weight loss of 28.3% at the highest dose 🚨The first phase 3 retatrutide

Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level

10.1016/S0140-6736(09)60659-0 149

Thus, more targeted, well-designed clinical trials are required for providing clearer evidence on the efficacy, optimal dose, and safety profiles of these drugs in AD and PD

Any prescription, if provided, is reviewed and approved by a licensed healthcare provider based on your individual medical history, eligibility, state availability, and clinical appropriateness - approval is never automatic

That would be expected, given that obesity and excess weight are risk factors for heart attack and stroke

Studies in mice demonstrated that liraglutide-induced C-cell proliferation was dependent on the GLP-1 receptor and that liraglutide did not cause activation of the REarranged during Transfection (RET) proto-oncogene in thyroid C-cells